CRA recently updated its 2011 review of health technology assessment (HTA) policies, and widened the assessment to cover 16 countries including emerging markets that have recently implemented HTA. Click the link below for a summary of key findings, with a link to the full report.
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...